Analysts have released updated earnings per share (EPS) estimates for a range of companies ahead of November 28th. This includes significant ratings changes for notable firms, reflecting shifts in market sentiment and analyst confidence.
Key Ratings Changes
Desjardins has initiated coverage on shares of Alamos Gold (NYSE:AGI) with a buy rating, indicating a positive outlook for the mining company. In contrast, Anheuser-Busch InBev SA/NV (NYSE:BUD) retained its buy rating from analysts at The Goldman Sachs Group, Inc., suggesting continued confidence in the beverage giant’s market performance.
Analysts at D. Boral Capital reaffirmed their buy rating for CollPlant Biotechnologies (NASDAQ:CLGN) with a target price set at $12.00. Meanwhile, CNH Industrial (NYSE:CNH) experienced a downgrade by JPMorgan Chase & Co., changing its rating from neutral to underweight with a target price of $10.00.
The outlook improved for Canadian National Railway (NYSE:CNI), as CIBC upgraded its rating from neutral to outperformer, increasing the target price to $151.00 from a previous $146.00.
Other Notable Adjustments
Analysts at JPMorgan Chase & Co. also upgraded Deutsche Boerse (OTCMKTS:DBOEY) from neutral to overweight, indicating a stronger position for the financial market operator. Similarly, easyJet (OTCMKTS:ESYJY) received an upgrade from Sanford C. Bernstein, moving from a market perform rating to outperform.
In a positive turn, Heineken (OTCMKTS:HEINY) saw its rating increased from hold to buy by analysts at Deutsche Bank Aktiengesellschaft. Additionally, Kinross Gold (NYSE:KGC) was also initiated with a buy rating by Desjardins, reflecting a favorable outlook in the precious metals sector.
Other adjustments include Moncler (OTCMKTS:MONRY), upgraded by JPMorgan Chase & Co. from neutral to overweight, and Netflix (NASDAQ:NFLX), which had its buy rating reiterated by Rosenblatt Securities, though the target price decreased slightly to $152.00 from $153.00.
Conversely, Prada (OTCMKTS:PRDSY) faced a downgrade from buy to neutral by UBS Group AG, indicating a less favorable outlook. Lastly, Travere Therapeutics (NASDAQ:TVTX) maintained its buy rating with a price target of $47.00, as reaffirmed by HC Wainwright.
These updates reflect a dynamic environment in the stock market, with analysts adjusting their views based on recent performance and market conditions. For investors, keeping abreast of these changes may provide valuable insights into potential investment opportunities.
